Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
